FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis

MYMDDelisted Stock  USD 1.82  0.02  1.09%   
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
MyMD Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company committed to developing novel therapi

Read at businesswire.com
businesswire News
  

MyMD Pharmaceuticals Fundamental Analysis

We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

MyMD Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

MyMD Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

MyMD Pharmaceuticals Related Equities

UBXUnity Biotechnology   4.17   
0%
91.0%
RXRXRecursion Pharmaceuticals   3.58   
0%
78.0%
GOVXGeoVax Labs   2.26   
0%
49.0%
DSGNDesign Therapeutics   2.25   
0%
49.0%
BOLTBolt Biotherapeutics   2.00   
0%
43.0%
KZRKezar Life   1.86   
0%
40.0%
NVCTNuvectis Pharma   1.53   
0%
33.0%
XBIOXenetic Biosciences   1.47   
0%
32.0%
REPLReplimune   1.30   
0%
28.0%
LYRALyra Therapeutics   1.18   
0%
25.0%
AVIRAtea Pharmaceuticals   0.31   
0%
6.0%
PASGPassage Bio   0.15   
0%
3.0%
SRZNSurrozen   0.08   
0%
1.0%
NBYNovaBay Pharmaceuticals     
0%
1.0%
LGNDLigand Pharmaceuticals   0.37   
8.0%
0%
KRONKronos Bio   1.04   
22.0%
0%
LYELLyell Immunopharma   1.61   
35.0%
0%
ORICOric Pharmaceuticals   1.68   
36.0%
0%
GOSSGossamer Bio   2.33   
51.0%
0%
KROSKeros Therapeutics   2.39   
52.0%
0%
REVBRevelation Biosciences   3.23   
70.0%
0%
LRMRLarimar Therapeutics   4.55   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in MyMD Stock

If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Share Portfolio
Track or share privately all of your investments from the convenience of any device